VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study

International Journal of Cancer

Volumn 135, Issue 5, 2014, Pages 1247-1256

  Scartozzi, Mario ^a   Faloppi, Luca ^a   Svegliati Baroni, Gianluca ^a   Loretelli, Cristian ^b   Piscaglia, Fabio ^c   Iavarone, Massimo ^d   Toniutto, Pierluigi ^e   Fava, Giammarco ^f   De Minicis, Samuele ^a   Mandolesi, Alessandra ^a   Bianconi, Maristella ^a   Giampieri, Riccardo ^a   Granito, Alessandro ^c   Facchetti, Floriana ^d   Bitetto, Davide ^e   Marinelli, Sara ^c   Venerandi, Laura ^c   Vavassori, Sara ^d   Gemini, Stefano ^a   D'Errico, Antonietta ^c   Colombo, Massimo ^d   Bolondi, Luigi ^c   Bearzi, Italo ^a   Benedetti, Antonio ^a   Cascinu, Stefano ^a   more..

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF UDINE   (Italy)

^f OSPEDALI RIUNITI   (Italy)

Author keywords

angiogenesis; hepatocellular carcinoma; rs2010963; rs4604006; single nucleotide polymorphisms; sorafenib; VEGF

Indexed keywords

SORAFENIB; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; DRUG DOSE REDUCTION; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; VEGF GENE; VEGFR GENE;

ANGIOGENESIS; HEPATOCELLULAR CARCINOMA; RS2010963; RS4604006; SINGLE NUCLEOTIDE POLYMORPHISMS; SORAFENIB; VEGF;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOTYPE; HUMANS; LIVER NEOPLASMS; LYMPHANGIOGENESIS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84902537135     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28772     Document Type: Article

References (44)

1. Nordenstedt H, White DL, El-Serag HB,. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010; 42 (Suppl 3): S206-S214.
2. Faloppi L, Scartozzi M, Maccaroni E, et al. Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. Cancer Treat Rev 2011; 37: 169-77.
3. Kane RC, Farrell AT, Madabushi R, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist 2009; 14: 95-100.
4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
5. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
6. Iavarone M, Cabibbo G, Piscaglia F, et al.; SOFIA (SOraFenib Italian Assessment) Study Group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011; 54: 2055-63.
7. Llovet JM, Peña CE, Lathia CD, et al.; SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2290-300.
8. Montella L, Addeo R, Caraglia M, et al. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience. Oncol Rep 2008; 20: 385-90.
9. Pages G, Puyssegur J,. Transcriptional regulation of the vascular endothelial growth factor gene-a concert of activating factors. Cardiovascular Res 2005; 65: 564-73.
10. Pander J, Gelderblom H, Guchelaar HJ,. Pharmacogenetics of EGFR and VEGF inhibition. Drug Discov Today 2007; 12: 1054-60.
11. Minchenko A, Salceda S, Bauer T, et al. Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 1994; 40: 35-9.
12. Vaziri SAJ, Kim J, Ganapathi MK, et al. Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. Curr Oncol Rep 2010; 12: 102-8.
13. Schultz A, Lavie L, Hochberg I, et al. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 1999; 100: 547-52.
14. Watson CJ, Webb NJ, Bottomley MJ, et al. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000; 12: 1232-5.
15. Renner W, Kotschan S, Hoffmann C, et al. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000; 37: 443-8.
16. Koukourakis MI, Papazoglou D, Giatromanolaki A, et al. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004; 46: 293-8.
17. Hansen TF, Garm Spindler KL, Andersen RF, et al. The predictive value of genetic variations in the vascular endothelial growth factor gene A in metastatic colorectal cancer. Pharmacogenomics J 2011; 11: 53-60.
18. Hansen TF, Sørensen FB, Spindler KL, et al. Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. Virchows Arch 2010; 456: 251-60.
19. Scartozzi M, Loretelli C, Galizia E, et al. Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. PLoS One 2012; 7: e38192.
20. Scartozzi M, Bianconi M, Faloppi L, et al. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first line sunitinib. Br J Cancer 2013; 108: 1126-32.
21. Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in trial of paclitaxel compared with paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 20: 4672-8.
22. Schultheis AM, Lurje G, Rhodes KE, et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008; 14: 7554-63.
23. Steffensen KD, Waldstrom M, Brandslund I, et al. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 2010; 117: 109-16.
24. Lencioni R, Llovet JM,. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
25. Center for Excellence and Technologic Innovation in Bioimaging. Available at: http://pupasuite.bioinfo.cipf.es/index.jsf. Accessed June, 2012.
26. National Centre for Biotechnology Information (NCBI) CIPF Single Nucleotide Polymorphism database. Available at: http://www.ncbi.nlm.nih.gov/SNP. Accessed June, 2012.
27. Chen MH, Tzeng CH, Chen PM, et al. VEGF-406T→ polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma. Pharmacogenomics J 2011; 11: 227-36.
28. Formento JL, Etienne-Grimaldi MC, Francoual M, et al. Influence of the VEGF-A 936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer. Pharmacogenomics 2009; 10: 1277-83.
29. North Carolina State University. Available at: www.statgen.ncsu.edu/ powermarker. Accessed June, 2012.
30. Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009; 115: 428-36.
31. Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumour control in hepatocellular carcinoma patients treated whit sorafenib. Oncologist 2010; 15: 85-92.
32. Di Costanzo GG, Tortora R, Iodice L, et al. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. Dig Liver Dis 2012; 44: 788-92.
33. Cai J, Ma H, Huang F, et al. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World J Surg Oncol 2013; 28: 306.
34. Estfan B, Byrne M, Kim R,. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol 2013; 36: 319-24.
35. Miyahara K, Nouso K, Tomoda T, et al. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2011; 26: 1604-11.
36. Personeni N, Bozzarelli S, Pressiani T, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol 2012; 57: 101-7.
37. Kamoun M, Houman MH, Hamzaoui A, et al. Vascular endothelial growth factor gene polymorphisms and serum levels in Behcet's disease. Tissue Antigens 2008; 72: 581-7.
38. Ruggiero D, Dalmasso C, Nutile T, et al. Genetics of VEGF serum variation in human isolated populations of cilento: importance of VEGF polymorphisms. PLoS One 2011; 6: e16982.
39. Al-Habboubi HH, Mahdi N, Abu-Hijleh TM, et al. The relation of vascular endothelial growth factor (VEGF) gene polymorphisms on VEGF levels and the risk of vasoocclusive crisis in sickle cell disease. Eur J Haematol 2012; 89: 403-9.
40. Zhai R, Gong MN, Zhou W, et al. Genotypes and haplotypes of the VEGF gene are associated with higher mortality and lower VEGF plasma levels in patients with ARDS. Thorax 2007; 62: 718-22.
41. Ferrante M, Pierik M, Henckaerts L, et al. The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 870-8.
42. Krippl P, Langsenlehner U, Renner W, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003; 106: 468-71.
43. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002; 51: 1635-9.
44. Petrovic MG, Korosec P, Kosnik M, et al. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol Vis 2008; 14: 1382-7.